AKBA

Akebia Therapeutics, Inc. NASDAQ Listed Mar 20, 2014

Healthcare ·Biotechnology ·US · akebia.com

$1.48

After hrs $1.47 -0.68%

Mkt Cap $397.0M

52w Low $1.14 11.6% of range 52w High $4.08

50d MA $1.38 200d MA $2.08

P/E (TTM) -67.3x

EV/EBITDA 20.5x

P/B 11.0x

Debt/Equity 6.6x

ROE -16.4%

P/FCF 6.1x

RSI (14) —

ATR (14) —

Beta 0.37

50d MA $1.38

200d MA $2.08

Avg Volume 3.0M

About

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adul…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.03	-0.05	-66.7%	1.32	-1.5%	-0.8%	-4.5%	-7.6%	-5.3%	-9.8%	—
Nov 10, 2025	AMC	-0.06	0.00	+103.3%	1.67	+0.6%	+8.4%	+10.8%	+5.4%	+0.0%	+5.4%	—
Aug 7, 2025	AMC	-0.02	0.00	+104.5%	3.01	+1.7%	+13.6%	+11.3%	+10.3%	+9.6%	+9.3%	—
May 8, 2025	AMC	-0.03	0.03	+200.0%	2.62	+0.0%	-2.7%	-7.3%	-5.3%	-6.5%	-3.1%	—
Mar 13, 2025	AMC	-0.05	-0.10	-100.0%	1.69	+4.7%	+33.7%	+42.0%	+50.9%	+68.0%	+20.7%	—
Nov 7, 2024	AMC	-0.05	-0.10	-100.0%	1.87	-1.6%	+3.7%	+6.4%	+4.3%	+2.7%	-0.5%	—
Aug 8, 2024	AMC	-0.06	-0.04	+33.3%	1.19	+0.0%	-6.7%	+3.4%	+12.6%	+13.4%	+21.0%	—
May 9, 2024	AMC	-0.09	-0.09	+0.0%	1.33	-6.0%	-9.0%	-3.0%	-7.5%	-11.3%	-14.3%	—
Mar 14, 2024	AMC	0.00	0.00	+99.4%	1.37	+16.8%	+24.1%	+38.0%	+33.6%	+41.6%	+48.9%	—
Nov 8, 2023	AMC	-0.09	-0.08	+11.1%	0.96	+1.0%	-5.2%	-7.0%	-3.8%	+7.3%	+4.2%	—
Aug 25, 2023	AMC	-0.03	-0.06	-140.0%	1.15	+7.0%	+20.0%	+33.9%	+21.7%	+20.9%	+15.7%	—
May 8, 2023	AMC	-0.15	-0.14	+6.7%	1.06	-3.8%	-0.9%	-2.8%	+0.0%	+6.6%	+2.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 7	BTIG	Maintains	Buy → Buy	—	$1.32	$1.32	+0.0%	+4.5%	+8.3%	+6.8%	+6.1%	+11.4%
Feb 25	BTIG	Maintains	Buy → Buy	—	$1.24	$1.25	+0.8%	-2.4%	+6.5%	+5.6%	+1.6%	-1.6%
Feb 6	Piper Sandler	Maintains	Overweight → Overweight	—	$1.38	$1.36	-1.4%	+0.7%	+8.7%	+9.4%	+12.3%	-1.4%
Feb 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.38	$1.36	-1.4%	+0.7%	+8.7%	+9.4%	+12.3%	-1.4%
Dec 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.51	$1.51	+0.0%	-2.6%	+4.0%	+5.3%	+2.0%	+7.3%
Dec 2	BTIG	Maintains	Buy → Buy	—	$1.51	$1.51	+0.0%	-2.6%	+4.0%	+5.3%	+2.0%	+7.3%
Oct 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.10	$2.09	-0.5%	+0.0%	+5.2%	+1.0%	-0.5%	+1.0%
Oct 29	BTIG	Maintains	Buy → Buy	—	$3.09	$2.16	-30.1%	-32.0%	-32.0%	-28.5%	-31.4%	-32.4%
Apr 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.88	$1.83	-2.7%	-5.9%	-5.9%	-10.6%	-9.6%	-17.6%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.69	$1.77	+4.7%	+33.7%	+42.0%	+50.9%	+68.0%	+20.7%
Mar 14	Piper Sandler	Maintains	Overweight → Overweight	—	$1.69	$1.77	+4.7%	+33.7%	+42.0%	+50.9%	+68.0%	+20.7%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.39	$2.38	-0.4%	+0.0%	-0.4%	-3.8%	-4.2%	-3.8%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.87	$1.90	+1.6%	+1.1%	+3.7%	+3.2%	+10.7%	+26.7%
Oct 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.64	$1.69	+3.0%	-3.0%	-3.7%	-3.0%	-0.6%	+4.3%
Oct 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.28	$1.28	+0.0%	+0.0%	+3.1%	+3.1%	+2.3%	+3.9%
Oct 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.32	$1.30	-1.5%	+0.0%	-3.0%	-3.0%	+0.0%	+0.0%
Sep 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.38	$1.39	+0.7%	-2.2%	+2.9%	+7.2%	+4.3%	+4.3%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.11	$1.17	+5.4%	+10.8%	+20.7%	+21.6%	+29.7%	+29.7%
Mar 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.24	$2.47	+10.3%	-18.3%	-27.2%	-29.5%	-33.5%	-32.6%
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.37	$1.60	+16.8%	+24.1%	+38.0%	+33.6%	+41.6%	+48.9%
Nov 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.99	$1.02	+3.1%	+1.1%	+3.1%	-0.4%	+0.1%	+1.1%
Sep 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.17	$1.21	+3.4%	-1.7%	-4.3%	-2.6%	-1.7%	-10.3%
Aug 28	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$1.15	$1.23	+7.0%	+20.0%	+33.9%	+21.7%	+20.9%	+15.7%
Aug 11	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.47	$1.38	-6.1%	-14.3%	-10.2%	-10.9%	-14.3%	-15.0%
Jun 21	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.13	$1.13	+0.0%	-3.5%	-7.1%	-9.7%	-19.5%	-17.7%
Jun 14	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.23	$1.24	+0.8%	-4.1%	-7.3%	-9.8%	-8.1%	-11.4%
Jun 2	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.09	$1.12	+2.8%	+0.9%	+2.8%	+10.1%	+17.4%	+14.7%
May 31	Piper Sandler	Upgrade	Neutral → Overweight	—	$0.96	$1.12	+16.8%	+8.4%	+13.7%	+14.7%	+16.8%	+25.1%
May 30	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.13	$1.26	+11.5%	-15.1%	-8.0%	-3.5%	-2.7%	-0.9%
May 26	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$1.21	$1.21	+0.0%	-6.6%	-20.7%	-14.0%	-9.9%	-9.1%
Apr 26	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$0.71	$0.71	-0.3%	+11.1%	+27.7%	+27.3%	+22.3%	+23.8%
Feb 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$0.65	$0.67	+3.1%	+5.8%	+13.1%	+26.1%	+24.8%	+28.9%
May 16	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$0.45	$0.35	-20.9%	-15.4%	-17.8%	-25.6%	-22.9%	-26.5%
Mar 31	Piper Sandler	Downgrade	Overweight → Neutral	—	$0.83	$0.78	-5.9%	-13.4%	-19.4%	-20.5%	-27.0%	-31.2%
Mar 31	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$0.83	$0.78	-5.9%	-13.4%	-19.4%	-20.5%	-27.0%	-31.2%
Mar 31	Mizuho	Downgrade	Buy → Neutral	—	$0.83	$0.78	-5.9%	-13.4%	-19.4%	-20.5%	-27.0%	-31.2%
Mar 31	Needham	Downgrade	Buy → Hold	—	$0.83	$0.78	-5.9%	-13.4%	-19.4%	-20.5%	-27.0%	-31.2%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.77	$2.88	+4.0%	+6.5%	+3.6%	+3.6%	+2.5%	+1.1%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.41	$3.52	+3.2%	-2.3%	+5.6%	+3.2%	+9.1%	+5.9%
Jan 29	JP Morgan	Downgrade	Neutral → Underweight	—	$3.43	$3.36	-2.0%	-5.5%	-0.6%	+2.0%	+14.9%	+12.8%
Oct 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.18	$3.10	-2.5%	-10.7%	-23.9%	-26.4%	-28.6%	-30.2%
Sep 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.65	$2.83	+6.8%	+2.6%	-1.9%	+0.0%	-1.9%	-4.5%
Sep 4	BTIG	Maintains	Buy → Buy	—	$2.65	$2.83	+6.8%	+2.6%	-1.9%	+0.0%	-1.9%	-4.5%
Sep 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.65	$2.83	+6.8%	+2.6%	-1.9%	+0.0%	-1.9%	-4.5%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$11.91	$12.26	+2.9%	+3.7%	+3.1%	+3.8%	+8.1%	+4.5%
May 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.95	$11.95	+0.0%	-2.6%	-2.3%	+0.3%	+7.5%	-3.2%
May 6	H.C. Wainwright	Maintains	Buy → Buy	—	$11.95	$11.95	+0.0%	-2.6%	-2.3%	+0.3%	+7.5%	-3.2%
May 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$11.95	$11.95	+0.0%	-2.6%	-2.3%	+0.3%	+7.5%	-3.2%
May 6	Mizuho	Maintains	Buy → Buy	—	$11.95	$11.95	+0.0%	-2.6%	-2.3%	+0.3%	+7.5%	-3.2%
May 6	JP Morgan	Maintains	Overweight → Overweight	—	$11.95	$11.95	+0.0%	-2.6%	-2.3%	+0.3%	+7.5%	-3.2%

Recent Filings

8-K

Unknown — 8-K Filing

A new director's option grant at $1.41 suggests management expects stock appreciation, but the low strike price indicates current valuation challenges that investors should monitor carefully.

Apr 1

8-K

Unknown — 8-K Filing

Q32 Bio's upcoming 36-week topline results for bempikibart in alopecia areata represent a critical near-term catalyst that could validate the drug candidate and significantly impact the stock's valuation.

Mar 10

8-K

Seres Therapeutics, Inc. -- 8-K Filing

Seres Therapeutics appointed a new executive with proven experience leading anemia programs at Akebia and managing acquisitions, strengthening its operational and clinical development capabilities.

Mar 2

8-K

Akebia Therapeutics, Inc. -- 8-K Filing

Akebia Therapeutics reports full-year 2025 results with positive early 2026 commercial momentum for its kidney disease treatment Vafseo, suggesting improved market adoption following its first-year launch.

Feb 26

Data updated apr 24, 2026 5:05pm · Source: massive.com